Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
McKesson
AstraZeneca
Harvard Business School
Boehringer Ingelheim

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR ANASTROZOLE


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Anastrozole

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Dosage NCT01300351 ↗ Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women Completed AstraZeneca Phase 3 2011-03-01 The purpose of this study is to evaluate the efficacy of a new dose of 500mg Fulvestrant with the standard dose of 250mg in Chinese postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed a prior endocrine treatment.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Anastrozole

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002644 ↗ Tamoxifen for the Prevention of Breast Cancer in High-Risk Women Active, not recruiting Institute of Cancer Research, United Kingdom Phase 3 1994-01-01 The International Breast Cancer Intervention Study I (IBIS-I) was designed to investigate the use of tamoxifen in preventing breast cancer in women with a higher risk of developing the disease. Recruitment of women to IBIS-I ended in March 2001 and it recruited 7154 women from 36 centres in 9 countries. The results of the study showed that tamoxifen reduced the incidence of breast cancer by one third in these high risk women but with some serious side effects. IBIS-II was designed to continue the work started in IBIS-I by examining the role of anastrozole in the prevention of breast cancer which we hope will reduce breast cancer by even more than tamoxifen with less serious side effects.
NCT00002644 ↗ Tamoxifen for the Prevention of Breast Cancer in High-Risk Women Active, not recruiting Queen Mary University of London Phase 3 1994-01-01 The International Breast Cancer Intervention Study I (IBIS-I) was designed to investigate the use of tamoxifen in preventing breast cancer in women with a higher risk of developing the disease. Recruitment of women to IBIS-I ended in March 2001 and it recruited 7154 women from 36 centres in 9 countries. The results of the study showed that tamoxifen reduced the incidence of breast cancer by one third in these high risk women but with some serious side effects. IBIS-II was designed to continue the work started in IBIS-I by examining the role of anastrozole in the prevention of breast cancer which we hope will reduce breast cancer by even more than tamoxifen with less serious side effects.
NCT00003199 ↗ Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed National Cancer Institute (NCI) Phase 2 1997-11-01 This phase II trial studies how well giving combination chemotherapy and peripheral blood stem cell transplant followed by aldesleukin and sargramostim works in treating patients with inflammatory stage IIIB or metastatic stage IV breast cancer. Drugs used in chemotherapy, such as busulfan, melphalan, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed. Aldesleukin may stimulate the white blood cells to kill breast cancer cells. Giving aldesleukin together with sargramostim may kill more tumor cells
NCT00003199 ↗ Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed Fred Hutchinson Cancer Research Center Phase 2 1997-11-01 This phase II trial studies how well giving combination chemotherapy and peripheral blood stem cell transplant followed by aldesleukin and sargramostim works in treating patients with inflammatory stage IIIB or metastatic stage IV breast cancer. Drugs used in chemotherapy, such as busulfan, melphalan, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed. Aldesleukin may stimulate the white blood cells to kill breast cancer cells. Giving aldesleukin together with sargramostim may kill more tumor cells
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Anastrozole

Condition Name

Condition Name for Anastrozole
Intervention Trials
Breast Cancer 135
Metastatic Breast Cancer 17
Breast Neoplasms 16
Advanced Breast Cancer 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Anastrozole
Intervention Trials
Breast Neoplasms 226
Carcinoma 15
Neoplasms 9
Carcinoma in Situ 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Anastrozole

Trials by Country

Trials by Country for Anastrozole
Location Trials
Canada 125
Italy 104
Spain 93
Japan 78
China 70
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Anastrozole
Location Trials
California 51
Florida 42
Texas 42
New York 42
Massachusetts 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Anastrozole

Clinical Trial Phase

Clinical Trial Phase for Anastrozole
Clinical Trial Phase Trials
Phase 4 15
Phase 3 76
Phase 2/Phase 3 1
[disabled in preview] 136
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Anastrozole
Clinical Trial Phase Trials
Completed 143
Active, not recruiting 38
Recruiting 36
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Anastrozole

Sponsor Name

Sponsor Name for Anastrozole
Sponsor Trials
AstraZeneca 65
National Cancer Institute (NCI) 41
Novartis Pharmaceuticals 14
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Anastrozole
Sponsor Trials
Other 307
Industry 186
NIH 50
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Dow
Merck
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.